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Abstract 
The ivy leaves dry extract EA 575® is an approved cough remedy distributed in more than 
100 countries worldwide.  
The modes of action for its bronchospasmolytic, secretolytic, and anti-inflammatory effects 
remain poorly understood. Therefore, this work focuses on a contribution to these 
mechanisms.  
Within this work it is shown that the former investigated inhibition of β2-adrenergic receptor 
internalization arrives from an indirect inhibition of receptor phosphorylation by GRK2. Also 
the recruitment of β-arrestin2 to the β2-adrenergic receptor (β2AR) is shown to be diminished 
after EA 575® pre-treatment under stimulating conditions.  
With respect to anti-inflammatory effects, EA 575® reduces IL-6 secretion from murine 
macrophages after LPS stimulation. This effect is explained by a reduced NFκB 
transcriptional activity measured by a reporter gene assay based on luciferase activity in 
HEK and THP-1 cells. As assessed by immunostaining, the translocation of NFκB into the 
nucleus under stimulating conditions is also impaired, which is explained by a higher amount 
of bound NFκB to its inhibitor IκBα detected by a protein fragment complementation assay. 
This result is underlined with a lowered phosphorylation of IκBα and a heightened 
phosphorylation of NFκB subunit RelA at Ser536 after EA 575® pre-treatment and TNFα 
stimulation.  
Finally, it is demonstrated in HEK Nanoluc-PEST cells that NFκB transcriptional activity is 
diminished by β2-adrenergic stimulation and synergistically inhibited by EA 575® pre-
incubation. Interestingly, this effect is shown to be β-arrestin dependent. Whether or not this 
crosstalk contributes to the efficacy of EA 575® requires further investigation. 
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1. Introduction 
The ivy leaves dry extract EA 575® is used for the treatment of acute inflammations of the 
airways associated with cough and for the improvement of symptoms in chronic inflammatory 
bronchial diseases.  
Its bronchospasmolytic and secretolytic effects have been demonstrated in clinical studies [1, 
2]. The mechanism of action is based on increased β2-adrenergic responsiveness of the 
airways through inhibited β2-adrenergic receptor (β2AR) internalization under stimulating 
conditions, leading to increased receptor binding and formation of cAMP in alveolar type 2 
cells (A549) and human airway smooth muscle (HASM) cells [3]. The molecular mechanism 
for the inhibited receptor internalization remained unclear.  
Besides bronchospasmolytic and secretolytic effects, there is growing evidence for an anti-
inflammatory effect of EA 575®. Zeil et al. performed a proof of concept study demonstrating 
that EA 575® as an add-on is beneficial in the treatment of partial or uncontrolled mild 
persistent allergic asthma in children [4]. Lung function was improved indicated by increased 
values of in MEF75-25, MEF25 and VC after treatment with EA 575®. As asthma is a chronic 
inflammatory disease, EA 575® was investigated for possible anti-inflammatory effects. In-
vivo it was already shown that a, not further defined, ivy extract exhibited anti-inflammatory 
properties in carrageenan- and cotton-pellet- induced inflammation in rats [5]. In-vitro studies 
have so far only engaged with single compounds of ivy leaves dry extracts. For example, 
rutin was shown to influence the NFκB pathway [6, 7].  
The aim of this work was, first, to examine the mode of action in which EA 575® inhibits β2AR 
internalization. Therefore, a possible effect of α-hederin on β2AR phosphorylation at 
Ser355/356 required for receptor internalization was studied. Additionally, the influence of EA 
575® on the recruitment of β-arrestin 2 to the β2AR was examined.  
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To investigate the effects of EA 575® on inflammatory processes the following further studies 
were performed:  
1. The secretion of IL-6 from murine macrophages was measured. 
2. NFκB translocation into the nucleus was examined. 
3. NFκB transcriptional activity was investigated with a reporter gene assay. 
4. Phosphorylation of IκBα and NFκB subunit RelA was assessed by western blot.  
5. The stability of NFκB:IκBα complex was measured in a protein fragment 
complementation assay. 
Furthermore, the impact of EA 575® on the crosstalk between β2AR signaling and NFκB 
pathway and the relevance of β-arrestins in these processes were investigated using NFκB 
reporter gene assays and protein fragment complementation measurements. 
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2 Materials  
2.1 Table 1: Cell lines 
 
Name Cell type Supplied by Reference  number 
CHO K1 ADRB2 
eXpress cells 
Chinese ovarian 
hamster cells 
overexpressing 
β2AR and β-
arrestin2 + β-gal 
EFC 
DiscoverX, Fremont, 
California, USA 
NM_000024 
HEK 293 Human embryonic 
kidney cells 
Deutsche Sammlung 
von Mikroorganismen 
und Zellkulturen 
(DSMZ) GmbH 
Braunschweig, 
Germany  
ACC 305 
THP-1  Human acute 
monocytic leukemia 
cells 
DSMZ ACC 16 
J774.2 BALB/C monocyte 
macrophages 
Sigma-Aldrich, 
Darmstadt, Germany 
85011428 
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2.2 Table 2: Bought solutions 
Name  Abbreviation Supplied by Reference number  
β-mercaptoethanol  Gibco/Thermo Fisher 
Scientific, Waltham, 
Massachusetts, USA 
31350010 
 
Dulbecco´s modified 
eagle medium 
DMEM Gibco 31885049 
Dulbecco´s modified 
eagle medium, 
without phenol red 
DMEM without 
phenol red 
Gibco 31053-028 
Draq5 - Thermo Fisher 
Scientific 
62251 
Fetal calf serum FCS Gibco 10270 
Glutamax 100x Glutamax Gibco 35050061 
L-Glutamine - Gibco 25300054 
Hank´s balanced salt 
solution 
HBSS Gibco 14025050 
Nano-Glo® 
Luciferase Assay 
system 
- Promega, Madison, 
Wisconsin, USA 
N1120 
Novex® mouse IL-6 
ELISA kit 
- Thermo Fisher 
Scientific 
KMC0061 
Odyssey blocking - LI-COR, Lincoln, 927-50000 
Materials 
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buffer (TBS) Nebraska, USA 
Penicillin-
streptomycin 10000 
U/ml 
P/S Gibco 15140122 
Phosphate buffered 
saline 
PBS Gibco 10010056 
REVERT LI-COR 
total protein stain kit  
REVERT LI-COR 926-11016 
Roswell Park 
Memorial Institute 
1640 Medium 
RPMI Gibco 31870-025 
Sapphire700 - LI-COR 928-40022 
Trypsin EDTA 0.05 
%, phenol red 
Trypsin Gibco 25300104 
 
  
Materials 
 
6 
 
2.3 Table 3: Self-made solutions 
Name Abbreviation Composition 
2x HEPES buffered 
saline  
2xHBS 42 mM HEPES 
274 mM NaCl 
10 mM KCl 
1.4 mM Na2HPO4 x 2H2O 
15 mM Glucose 
Adjusted to 
pH 7.13 
Electroporation 
buffer for THP-1 cells 
- 5 mM KCl,  
15 mM MgCl2,  
15 mM HEPES 
50 mM NaCl 
150 mM 
Na2HPO4/NaH2PO4 pH 7.2 
Lysogeny broth-
medium 
LB-medium 
 
1% (w/v) Bacto-tryptone 
0.5 % (w/v) Bacto-yeast extract  
1% (w/v) NaCl  
pH 7.0 
Phosphate buffered 
saline 
PBS 137 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 
1.8 mM K2HPO4 
adjusted with NaOH to pH 7.4  
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Phosphate buffered 
saline with 0.1 % 
Tween 20  
PBS/T 137 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 
1.8 mM K2HPO4 
adjusted with NaOH to pH 7.4 
+ 0.1 % Tween 20  
Tris, acetic acid, 
EDTA buffer 
TAE buffer 40 mM Tris  
20 mM acetic acid 
1 mM EDTA 
Tris buffered saline TBS 150 mM NaCl 
50 mM Tris-Cl  
Adjusted with NaOH to pH 7.4 
Tris buffered saline 
with 0.1 % Tween 20  
 
TBS/T 150 mM NaCl 
50 mM Tris-Cl  
Adjusted with NaOH to pH 7.4 
+ 0.1 % Tween 20  
Tris buffered saline 
with 0.1 % Tween 20 
and 0.01 % SDS  
TBS/TS 150 mM NaCl 
50 mM Tris-Cl  
Adjusted with NaOH to pH 7.4 
+ 0.1 % Tween 20  
+ 0.01 % SDS 
Tris buffered saline 
with 0.1 % Triton X 
100  
TBS/X 150 mM NaCl 
50 mM Tris-Cl  
Adjusted with NaOH to pH 7.4 
+ 0.1 % Triton X 100  
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2.4 Table 4: Antibodies 
 
Host and antigene Supplied by Reference number  
Mouse anti RelA Cell Signaling Technologies, Danvers, 
Massachusetts, USA 
6956 
Rabbit anti Ser536 
phosphorylated RelA 
Cell Signaling Technologies 3033 
Rabbit anti Ser32 
phosphorylated IκB  
Cell Signaling Technologies 9246 
Goat anti-Mouse Cy3 
conjugated  
Thermo Fisher Scientific A10521 
Rabbit anti pβ2-AR355/356 Santa Cruz Biotechnology, Dallas, 
Texas, USA 
Sc-16719-R 
Goat anti-Rabbit IRDye® 
800 CW 
LI-COR  925-32211 
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2.5 Table 5: Chemicals  
 
 
  
Name Supplied by Reference number 
α-Hederin Phytolab, Vestenbergsgreuth, Germany 89220 
Corticosterone Sigma-Aldrich 46148 
3,4- Dicaffeoylquinic acid Phytolab 80425 
3,5- Dicaffeoylquinic acid  Phytolab 80426 
4,5- Dicaffeoylquinic acid Phytolab 80427 
Hederacoside B Stanford Chemicals, California, USA - 
Hederacoside C Phytolab 89221 
Hederacoside D Phytolab 84218 
ICI 118,551 hydrochloride  Sigma-Aldrich I127 
Lipopolysaccharide from 
E. coli  
Sigma-Aldrich L2630 
Kaempferol-3-O-rutinoside Phytolab 80700 
Paroxetine hydrochloride 
hemihydrate  
Sigma-Aldrich P9623 
Rutin Phytolab 89270 
Terbutaline hemisulfate Sigma-Aldrich T2528 
Tumor necrosis factor α Merck Millipore, Massachusetts, USA GF314 
Methods 
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3 Methods 
3.1 Characterization of EA 575® by HPLC analysis 
EA 575® (CID-100048) was dissolved in 50 % EtOH in a concentration of 40.8 mg/ml.        
EA 575® was filtrated through a 0.45 µm PTFE filter and analyzed on a Agilent Series 1200 
HPLC system equipped with a degasser (G1322A), a quaternary pump (G1311A), an 
autosampler (G1329A), and a photodiode array detector (G1315D) using a LiChrospher RP-
18 column (5 µm, 125 x 4 mm, Merck, Darmstadt). Solvent A was H2O/acetonitrile (44/2, 
m/m) adjusted to pH 2.0 with phosphoric acid 85 %. Solvent B was acetonitrile. The following 
linear gradient was used: 0-9 min 0 % B, 9-10 min to 6 % B, 10-25 min to 15 % B, 25-50 min 
to 60 % B, 50-51 min to 100 % B, 51-65 min 100 % B. Flow rate: 0-50 min 1 ml/min, 51-65 
min 1.5 ml/min. Detection: 205 nm. Identification of rutin, 3,4-dicaffeoylquinic acid (3,4-DCA), 
3,5-dicaffeoylquinic acid (3,5-DCA), 4,5-dicaffeoylquinic acid (4,5-DCA), kaempferol-3-O-
rutinoside, hederacoside C, hederacoside D, hederacoside B, and α-hederin was carried out 
by comparison of UV spectra of reference substances and their corresponding retention 
times, as shown in supplemental material (Table S 1). α-Hederin amount was quantified by 
the determination of reference peak area equal to 1 µg α-hederin and the corresponding area 
in extract analysis. The calculations and a reference chromatogram are shown in 
supplemental material (Table S 2, Table S 3, and Figure S 1). The integration parameters 
were set to a slope sensitivity of 5, a peak width of 0.05, an area reject of 20, an height reject 
of 1, and shoulders off. The chromatograms were registered and evaluated using Agilent 
Chemstation Software Version B.04. 
3.2 Cell culture 
HEK 293 cells, subsequently called HEK cells, were cultivated in DMEM supplemented with 
5 ml P/S and 10 % FCS for 500 ml medium. HEK cells and all constructed clones were 
subcultured 1:10 every 3-4 days in 10 cm cell culture dishes. THP-1 cells were maintained in 
Methods 
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a RPMI medium supplemented with 10 % FCS, 5 ml P/S, 50 µM β-mercaptoethanol and 5 ml 
Glutamax for 500 mL medium. THP-1 cells as well as the Nanoluc-PEST clone were 
subcultured 1:3 every 2-3 days in 75 cm2 flasks. J774.2 cells were cultured in a DMEM 
without phenol red supplemented with 5 ml P/S, 5 ml L-Glutamine and 10 % FCS for 500 ml 
medium, cells were subcultured 1:10 every 2-3 days in 10 cm plates. All cells were cultured 
at 37° C with 5 % CO2. 
3.3 Generation of NFκB reporter plasmid 
For the generation of a NanoLuciferase with an associated PEST sequence (Nanoluc-PEST) 
under control of an NFκB binding sequence the pNFκB-D2EGFP vector (Clontech) was used 
as origin. The destabilized GFP was removed from the vector by PCR, introducing a new 
XhoI-site (forward primer: 5’TCGGATATCTCGAGCCGGAATTCGGGGAAGCTTC-3’; reverse 
primer: 5’-GTTCAGGGGGAGGTGTG-3’). The Nanoluc-PEST sequence was cut from 
pNL1.2[NlucP] vector using BamHI/XhoI and introduced via ligation into the pNFκB vector. 
Ligation was performed for 1 h at room temperature by combining 1 Unit T4-DNA ligase with 
20 ng vector-DNA and 3fold amount of the insert-DNA fragment in 1x ligase buffer. 
Subsequently, the vector was recaptured from a 1 % agarose gel and amplified in XL1-blue 
cells as described in chapter 3.5. For analysis the vector was enzymatically digested by BglI 
and PstI and fragment sizes were matched. The found fragments corresponded to the 
expected fragment sizes of 4597+1299 for BglI enzymatic digest, and 3155+2741 for PstI 
enzymatic digest, respectively. The agarose gel of enzymatic digestions and the plasmid 
card are shown in the supplemental material (Figure S 2, Figure S 3). Integrity of the final 
construct was additionally confirmed by a cycle sequencing performed by GATC. 
3.4 Generation of IκBα-nVenus and RelA-cVenus 
The protein fragment complementation (PFC) plasmids, pCDNAHygr_cVenus-RelA and 
pCDNAZeo_IkBa-nVenus were constructed by GeneArt according to the publication of Yu et 
al. [8]. For verification, the plasmid pCDNAZeo_IkBa-nVenus was enzymatically digested 
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with BglI and PstI. The vector showed the expected band sizes in an agarose gel analysis. 
Also, pCDNAHygr_cVenus-RelA was enzymatically digested with EcoRI and showed the 
expected band sizes. The agarose gels of digestions and the plasmid cards are shown in the 
supplemental material (Figure S 4, Figure S 5, Figure S 6, and Figure S 7). The vector was 
amplified in XL1-blue as described in chapter 3.5. Integrity of the final construct was 
additionally confirmed by a cycle sequencing performed by GATC. 
3.5 Transformation of XL1-blue bacteria cultures 
For the amplification of the DNA constructs described above, approximately 1 ng of DNA was 
mixed with 100 μl competent XL-1 blue bacteria and the mixture was kept on ice for 30 min. 
A heat shock was performed by heating the mixture for 30 s at 42°C and suddenly cooling it 
on ice for 1 min. 
900 μl of pre-warmed LB medium was added to the bacteria–DNA mix and the mixture was 
incubated in a shaker at 37°C for 1 h. Afterwards, 100 to 500 μl of the DNA-bacterial cells 
mixture were spread on agar-LB-medium plates (1.5 % w/v agar in LB-medium) containing 
the same antibiotic as used for selection and incubated at 37°C overnight. Single clones 
arising from single bacterial cells were picked and inoculated each in 5 ml LB-medium 
containing the appropriate antibiotic (50 µg/ml ampicillin or 25 µg/ml kanamycin) and 
incubated at 37°C overnight in a shaker. The next day 500 µl of pre-culture was added to 25 
ml fresh, antibiotic containing LB-medium and allowed to grow for 8 h.  
Plasmid DNA was isolated by midi prep isolation kit (Qiagen®) according to the 
manufacturer’s instructions (Figure S 8), digested with the suitable restriction enzymes, and 
the correct insert size verified by agarose gel electrophoresis in comparison to a DNA 
standard ladder. 
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3.6  Agarose gel electrophoresis 
An agarose gel (1 %) was prepared by suspending the required amount of agarose in 1 x 
TAE buffer and heating in a microwave oven until the solution became clear. After cooling 
the solution down to approximately 55°C, ethidium bromide was added in a final 
concentration of 1 μg/ml and the mixture was allowed to polymerize in a prepared casting 
tray with a suitable comb size. After being completely polymerized, the gel was placed into 
an electrophoresis chamber filled with 1 x TAE buffer. The DNA samples were mixed with the 
sample buffer and slowly loaded into the wells before an electric current was applied (3-10 
V/cm2) for 30 min. Finally, DNA fragments were detected using an UV detector. 
3.7 Transfection of HEK cells  
HEK cells were transfected by calcium phosphate method. The cells were seeded in 12 well 
plates and allowed to attach for at least 24 h. Before transfection, the medium was changed 
to 900 µl fresh, fully supplemented medium. One µg DNA was mixed with 6.5 µl 2 M CaCl2 
and 50 µl sterile water. The mixture was added dropwise to 2x HBS pH 7.13 and after half an 
hour of resting added to the cells. After 24 h the medium was changed to fresh DMEM 
containing antibiotic for selection. After one week of selection single clone was picked by 
trypsination in a cloning ring and seeded in a distinct 12 well plate for further growth. For 
selection of Nanoluc-PEST clones 700 µg/ml geneticin, for IκBα-nVenus clones 150 µg/ml 
Zeocin and for RelA- cVenus clones 100 µg/ml Hygromycin was used, respectively. The 
cloning procedure of β2AR GFP plasmid and its transfection to HEK cells were described 
previously [3, 9]. HEK β-arrestin 1/2 KO cells were a kind gift of Asuka Inoue (Graduate 
School of Pharmaceutical Sciences, Tohoku University Japan). Asuko Inoue therefore 
modified HEK cells by CRISPR/Cas9 genome editing to eliminate β-arrestins (β- arrestin1 
and β-arrestin2), as described in the work of Alvarez-Curto et al [10]. 
Methods 
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3.8 Transfection of THP-1 cells 
THP-1 cells were transfected by Amaxa electroporation technology, Nucleofector® II. For 
each transfection 2x 106 cells were diluted in 100 µl of a self-made electroporation buffer with 
1 µg DNA and transfected with the program T-020. Afterwards they were transferred to a 12 
well plate with 1 ml fresh, fully supplemented RPMI medium. After 24 h the medium was 
changed to full medium containing 700 µg/ml geneticin for selection. Every 2-3 days the 
medium was changed by 10 min centrifugation with 90 rcf. After one week of selection the 
mixed clone grew up. 
3.9 In-Cell Western™ measurement for phosphorylated β2-adrenergic 
receptor (Ser355/356) 
96 well plates were coated with 40 µl of 0.1 mg/ml PDL for 30 min and afterwards washed 
three times with 50 µl PBS. HEK β2AR GFP cells were seeded in a fully supplemented 
growth medium in a density of 15000 cells per well and allowed to grow to a confluency of 80 
% and starved overnight in serum-free medium. Pre-incubation with α-hederin was 
performed for 8 h. Next morning GRK2 inhibition with 10 µM paroxetine was performed for 45 
min. The cells were stimulated with 1 µM terbutaline, or 0.5 µM isoprenaline, respectively, in 
serum-free medium for 20 min. Afterwards the fixation was done with 15 % sucrose 4 % PFA 
in PBS for 30 min. The permeabilization was performed with TBS/X five times for five min. 
Cells were blocked for 1 h with Odyssey blocking buffer and afterwards incubated with the 
primary antibody (rabbit anti pβ2AR355/356) diluted 1:200 in Odyssey blocking buffer for 2.5 
h. The goat-anti-rabbit IRDye800 antibody in a dilution of 1:800 in Odyssey blocking buffer 
supplemented with 0.05 %Tween 20 was used for the immunostaining. Additionally, the 
nuclei were stained with Draq5 and Sapphire700 in dilutions of 1:2000 and 1:1000, 
respectively. Immunostaining was done for 1 h in the dark. After the fixation step, the plate 
was washed 3 times with TBS/T in between each step. The dried plate was measured on an 
Odyssey classic reader in 700 and 800 nm channels. Calculation was done dividing data 
registered at 800 nm channel (phosphorylation) through the appropriate data registered at 
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700 nm channel (cell number), which is named as near-infrared ratio (NIR ratio), and 
normalizing it on the terbutaline or isoprenaline stimulated control, respectively.  
3.10 Dynamic mass redistribution measurements 
For the dynamic mass redistribution measurements, HEK, HEK β2AR GFP, and HEK β-
arrestin 1/2 KO cells were seeded in a density of 6000 cells per well in a 348 well plate 
(Corning: #5042) and allowed to grow in full growth medium to a confluency of 90 %. For the 
incubation with ivy leaves dry extract medium was changed to serum-free medium and cells 
were incubated with 40, 80, or 240 µg/ml EA 575® or 1 µM α-hederin respectively, for 8 h. 
Afterwards medium was replaced by HBSS buffer supplemented with 20 mM HEPES and the 
corresponding cells were incubated for 1 h with 10 µM paroxetine or ICI 118551, 
respectively, both in HBSS buffer supplemented with 20 mM HEPES. The compound plate 
was prepared with 4-fold concentrations of the used chemicals and loaded into a pipette 
robot at 37°C. The assay plate was loaded into the Corning® label free Epic® III reader at 
37°C and baseline acquisition was done for 300 sec before the stimulation was performed 
via the pipette robot with 10 µl of the 4-fold solutions of terbutaline or buffer alone. The 
measurement was recorded for 30 min. Results were documented as changes of the 
wavelength of the reflected light in pm over time.  
3.11 PathHunter® assay with CHO K1 ADRB2 eXpress cells 
CHO K1 ADRB2 eXpress cells were thawed and resuspended in 20 ml of the provided CP 
medium. One hundred µl cell suspension per well was seeded in a white 96 well plate 
included in the assay kit and allowed to grow for 24 h. The incubation was performed 
overnight with EA 575® or α-hederin in the indicated concentrations, respectively. Inhibition of 
GRK2 was done with 10 µM paroxetine for 45 min. Afterwards the cells were stimulated with 
1 µM terbutaline for 90 min. The detection of the chemiluminescent signal was carried out 
according to the manufacturer’s instructions (Figure S 11). The bottom side of the plate was 
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masked with a white non-transparent adhesive foil and the luminescence was measured in a 
Tecan Genios® plate reader.  
3.12 Determination of IL-6 in J774.2 cells 
For the IL-6 measurements J774.2 cells were seeded in 12 well plates at a density of 60000 
cells per well and were allowed to grow for 24 h. The increased release of IL-6 into the cell 
supernatant was induced by 10 ng/ml LPS for 12 h. Incubation of cells with 1.7 µg/ml (5 µM) 
corticosterone together with 10 ng/ml LPS for 12 h was used as a negative control. EA 575® 
was tested in concentrations of 40, 80 and 160 µg/ml incubated for 12 h simultaneous with 
LPS. The cell supernatants were used for IL-6 determination with a Novex® mouse IL-6 
ELISA kit according to the manufacturer´s instructions provided as supplemental material 
(Figure S 12). The absorbance was measured on a Tecan Genios ® Reader at 450 nm.  
3.13 Measurement of NFκB transcriptional activity through a Nanoluc-PEST 
reporter system in HEK Nanoluc-PEST and HEK β-arrestin 1/2 KO 
Nanoluc-PEST cells 
96 well LumiNunc™ plates were coated with 40 µl of 0.1 mg/ml PDL for 30 min and 
afterwards washed three times with 50 µl PBS. HEK cells or HEK β-arrestin 1/2 KO cells both 
stably expressing Nanoluc-PEST were seeded in a density of 15000 cells per well in 100 µl 
total growth medium and allowed to grow to a confluency of 90 %. The medium was changed 
to serum-, and antibiotic-free medium. Incubation was performed with 40, 80 or 240 µg/ml EA 
575® for 8 h, respectively. For the co-stimulation with terbutaline an incubation time of 8 h 
and a concentration of 1 µM was considered to be most promising. The best measurement 
conditions for TNFα were identified through a time- and dose-dependent measurement and 
were therefore set to a dose of 25 ng/ml and an incubation time of 3 h within the EA 575® 
and/or terbutaline incubation. (Figure S 14). Measurement of luciferase activity was achieved 
using the Nano-Glo® Luciferase Assay system as described in chapter 4.A and 4.B of the 
manual (Figure S 13). The bottom side of the plate was masked with a white non-transparent 
adhesive foil and luminescence was measured in a Tecan Genios® plate reader.  
Methods 
 
17 
 
3.14 Measurement of NFκB transcriptional activity through a Nanoluc-PEST 
reporter system in THP-1 cells 
THP-1 Nanoluc-PEST cells were seeded in 96 well LumiNunc™ plates in a density of 
100000 cells/ml and incubated immediately with 40, 80 or 240 µg/ml EA 575® for 8 h, 
respectively. After 5 h, LPS was added to a concentration of 10 ng/ml for 3 h which was 
decided upon time- and dose dependent measurements shown in the supplemental material 
(Figure S 15). The measurement of luciferase activity was performed using the Nano-Glo® 
Luciferase Assay system as described in chapter 4.A and 4.B of the manual (Figure S 13). 
The bottom side of the plate was masked with a white non-transparent adhesive foil and 
luminescence was measured in a Tecan Genios® plate reader.  
3.15 Immunolocalization of RelA in HEK cells 
Glass coverslips were coated with 0.1 mg/ml PDL for 30 min in 12 well plates and 
subsequently washed three times with PBS. HEK cells were seeded on the coverslips in a 
density of 100000 cells per well. At a cell confluency of 90 % medium was changed to plain 
medium and cells were incubated for 8 h with 240 µg/ml EA 575® or 0.5 % ethanol as a 
control. After 7 h and 10 min TNFα was added to a concentration of 25 ng/ml for 50 min. 
Afterwards the cells were fixed with freshly prepared 4 % formaldehyde in PBS, 
permeabilized with ice-cold methanol for 10 min and blocked with 5 % BSA in PBS 
supplemented with 0.3 % Triton X-100. The immunostaining was performed with an antibody 
targeting RelA in a dilution of 1:800 overnight and a Cy3 coupled secondary antibody in a 
dilution of 1:400 for 1.5 h in the dark. Additionally, cells were incubated with Hoechst 33528 
for a nuclear staining. For long-term storage cells were mounted on object slides with 
ProLong® antifade diamond. In between each step the cells were washed with PBS. After 
incubation with the secondary antibody the cells were additionally washed with deionized 
water. Images were taken on a Zeiss Axiovert 200 M with a LCI Plan-Neofluar 63x/1.30 Imm 
Korr Ph 3 M27 objective using an AxioCamHR.  
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3.16 Immunolocalization of RelA in J774.2 cells 
J774.2 cells were seeded on coverslips in a density of 100000 cells per well. After they 
reached a confluency of 90 %, the cells were incubated overnight with 80 µg/ml EA 575® or 
0.5 % ethanol. The following day cells were stimulated for 60 min with 100 ng/ml LPS. 
Afterwards the cells were fixed with 4 % formaldehyde in PBS, permeabilized with ice-cold 
methanol for 10 min and blocked with 5 % BSA in PBS supplemented with 0.3 % Triton X-
100 for 1 h. Immunostaining was performed with an antibody targeting RelA in a dilution of 
1:800 overnight and a Cy3 coupled secondary antibody in a dilution of 1:400 for 1.5 h in the 
dark. Additionally, cells were incubated with Hoechst 33528 for a nucleus staining. For long-
term storage cells were mounted on object slides with ProLong® antifade diamond. In 
between each step cells were washed with PBS. After incubation with the secondary 
antibody the cells were additionally washed with deionized water. Images were taken on a 
Zeiss Axiovert 200 M with a LCI Plan-Neofluar 63x/1.30 Imm Korr Ph 3 M27 objective using 
an AxioCamHR.  
3.17 Western blot analysis  
HEK cells were seeded in 12 well plates and allowed to grow to a confluency of 80-90 % in 
full-growth medium. The cells were incubated in a plain-medium with 240 µg/ml EA 575® for 
8 h and afterwards with 25 ng/ml TNFα for 10 min. After the incubation cells were harvested 
with 100 µl 10 mM HEPES buffer pH 7.4 per well containing the appropriate amounts of 
phosphatase inhibitor cocktail and protease inhibitor cocktail. Cell solutions were sonified for 
15 sec with 40 kHz and lysed by being forced through a 30 G cannula. To separate cell 
debris the solution was centrifuged with 15000 rcf for 5 minutes at 4°C. Fifteen µl 
supernatant was diluted with 5 µl 4x sample buffer NuPAGE® and 20 µl of the samples were 
separated in a 10 % acrylamide gel with 80 V in the stacking (5 %) and 120 V in the resolving 
gel. The blotting was done with 200 mA per gel in a semi-dry blotter for 45 min. For 
normalization the membrane was stained after blotting with REVERT™ total protein stain 
according to the manufacturer´s instructions supplied in the supplemental material (Figure S 
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19). The intensity was measured on a LI-COR Odyssey classic reader in 700 nm channel. 
Afterwards the stain was removed as described in the manual and the membrane was 
blocked with Odyssey blocking buffer (TBS) for 1 h. Detection of the phosphorylated proteins 
was performed by incubating the membrane in Odyssey blocking buffer diluted 1:1 with 
TBS/T containing the respective antibodies against phosphorylated IκBα or phosphorylated 
RelA in a dilution of 1:1000. After washing three times in TBS/T the membrane was 
incubated with secondary antibody (LI-COR Goat anti Rabbit IRDye800, 1:10000) in 
Odyssey blocking buffer diluted 1:1 with TBS/TS for 1 h. Membrane was washed three times 
in TBS and measured again on a LI-COR Odyssey classic Reader in 800 nm channel. The 
normalized protein concentration was received by dividing the signal intensity value of the 
phosphorylated protein by the respective normalization factor of REVERT™ total protein 
stain. 
3.18 Protein fragment complementation assay 
Black 96 well plates (CellCarrier™) were coated for 30 min with 0.1 mg/ml PDL in PBS. 
Residual PDL was removed by three washing steps with PBS. HEK cells stably expressing 
IκBα-nVenus and RelA-cVenus were seeded into these plates in total growth medium and 
allowed to grow to a confluency of 90 %. After reaching confluency the cells were pre-
incubated for 8 h with the indicated concentration of EA 575® in HBSS buffer supplemented 
with 20 mM HEPES. Terbutaline incubation was performed for 2 h in concentrations of 0.1, 1 
and 10 µM, respectively. After pre-incubation the cells were stimulated with 10 ng/ml TNFα 
and the decrease of fluorescence intensity was measured for 3 h in a Perkin Elmer EnSight 
reader with excitation at 515 nm and emission at 550 nm and normalized through the cell 
density determined by transmission pictures and analysis by Kaleido™ 2.0 software. 
3.19 Statistical data evaluation  
Statistical data evaluation was performed with One-way ANOVA followed by Tukey multiple 
comparison test. Results were considered to be significant for p-values < 0.05. 
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4 Results 
 
4.1 HPLC fingerprint analysis of EA 575® 
The used batch of EA 575® was analyzed by the described HPLC method. Rutin, 3,4-DCA, 
3,5-DCA, 4,5-DCA, kaempferol-3-O-rutinoside, hederacoside C, hederacoside D, 
hederacoside B, and α-hederin were identified in the HPLC chromatogram by comparison of 
both the retention time and the UV spectra of their corresponding reference substances. A 
table of the retention times of the identified EA 575® ingredients can be found in the 
supplemental material (Table S 1). α-Hederin was additionally quantified through the 
determination of the peak area in relation to the peak area corresponding to 1 µg of its 
reference substance. Calculation can be found in the supplemental material (Table S 3). The 
used extract concentrations are thereby adjusted to the contained α-hederin amount. 80 
µg/ml EA 575® correspond to 1 µM α-hederin.  
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Figure 1: HPLC chromatogram of EA 575®  
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4.2 Inhibition of β2-adrenergic receptor phosphorylation at Ser355/356 by α-
hederin 
As already published, it could be shown that α-hederin, a compound of the ivy leaves dry 
extract EA 575®, is able to inhibit the GRK2 mediated phosphorylation of β2AR [11]. For this 
study HEK β2AR GFP cells were stimulated with isoprenaline. Phosphorylation was 
measured in an In-Cell Western™ assay with a Ser355/356 phosphorylation specific 
antibody. α-Hederin dose-dependently decreased the isoprenaline induced β2AR 
phosphorylation at Ser355/356. A concentration of 0.5 µM α-hederin inhibited the 
phosphorylation by 17.0 %, while 1 µM α-hederin even reduced it by 20.4 % (Figure 2). 
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Figure 2: Phosphorylation of the β2AR at Ser355/356 measured in HEK β2AR GFP cells after 
8h pre-incubation with the indicated amounts of α-hederin and stimulation with 0.5 µM 
isoprenaline for additional 20 min. The presented data was generated in cooperation with 
Anne Wolf. Data represent the mean and S.D. of at least three independent experiments 
(n≥30, *p < 0.05).  
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4.3 Inhibition of β2-adrenergic receptor phosphorylation at Ser355/356 by 
paroxetine 
The study previously referred to, used methyl-5-[2-(5-nitro2-furyl)vinyl]-2-furoate as a GRK2 
inhibitor according to the publication of Iino et al. [12]. Later on, paroxetine was identified as 
a GRK2 inhibitor with a lower IC50 value and selectivity for GRK2 over e.g. GRK1 or GRK5, 
respectively [13]. Therefore in this work paroxetine was used as a GRK2 inhibitor. Usability 
was shown in an In-Cell Western™ assay by measuring phosphorylation of β2AR at 
Ser355/356 after terbutaline stimulation.  
Paroxetine was shown to inhibit the terbutaline induced and GRK2 mediated β2AR 
phosphorylation dose-dependently by 17.0, 24.4, and 32.0 %, respectively, in concentrations 
between 1 and 10 µM (Figure 3).  
 
Figure 3: Phosphorylation of the β2AR at Ser355/356 measured in HEK β2AR GFP cells after 
45 min pre-incubation with the indicated amounts of GRK2 inhibitor paroxetine and 
stimulation with 1 µM terbutaline for additional 20 min. Data represent the mean and S.D. of 
at least three independent experiments. (n≥27, *p < 0.05) 
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4.4 Dynamic mass redistribution assay 
Dynamic mass redistribution assays were established as a high throughput screening for 
several GPCRs [14]. Stimulation with an appropriate agonist induces a change in the 
reflected wavelength which can be measured. Terbutaline led to a dose- dependent positive 
wavelength shift in concentrations between 0.1 nM and 10 µM. 
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Figure 4: Dose-response of 0.1 nM to 10 µM terbutaline in dynamic mass redistribution 
measurements in HEK β2AR GFP cells. Shown is a representative experiment. 
 
The induced positive wavelength shift by 1 µM terbutaline was enhanced by pre-incubation 
with paroxetine, α-hederin, and EA 575®. Pre-incubation with ICI 118,551 almost completely 
abolished the terbutaline induced wavelength shift (Figure 5).  
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Figure 5: Dynamic mass redistribution measurements in HEK cells after pre-incubation with 
10 µM paroxetine or ICI 118,551 for 1 h, or with 1 µM α-hederin or 80 µg/ml EA 575®, 
respectively, for 8 h prior to stimulation with 1 µM terbutaline after 300 sec of baseline 
measurements. Measurements are representative for three independent experiments.  
 
To check whether or not β-arrestins are involved in the altered wavelength shift mediated by            
α-hederin, paroxetine, and EA 575®, respectively, the experiment was repeated with HEK β-
arrestin 1/2 KO cells  
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Figure 6: Dynamic mass redistribution measurements in HEK β-arrestin 1/2 KO cells after 
pre-incubation with 10 µM paroxetine or ICI 118,551 for 1 h, or with 1 µM α-hederin or 80 
µg/ml EA 575®, respectively, for 8 h prior to stimulation with 1µM terbutaline after 300 sec of 
baseline measurements. Measurements are representative for three independent 
experiments.  
In HEK β-arrestin 1/2 KO cells the terbutaline induced wavelength shift was not altered by 
pre-incubation with paroxetine, α-hederin, or EA 575®, respectively. Thus, the altered 
wavelength shift under stimulating conditions appears to be β-arrestin dependent. Similar to 
HEK cells the wavelength shift induced by terbutaline was abolished by pre-incubation with 
ICI 118,551 (Figure 6).  
4.5 PathHunter® assay for β-arrestin 2 recruitment 
 
Figure 7: Principle of the PathHunter® β-arrestin 2 assay. Illustration taken from [7]. 
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The GRK2 phosphorylation of β2AR is known to induce β-arrestin 2 recruitment and thereby 
trigger the internalization of the receptor [15]. Thus, GRK2 inhibition by α-hederin should also 
have an impact on the recruitment of β-arrestin 2.  
This was investigated by the above shown PathHunter ® β-arrestin 2 assay (Figure 7). 
Recruitment of β-arrestin 2 was induced by the stimulation with 0.5 µM terbutaline and 
almost totally inhibited by pre-incubation with the GRK2 inhibitor paroxetine. EA 575® 
showed a dose-depended decrease in β-arrestin 2 recruitment by 10.7, 20.2, and 26.3 %, 
respectively, in concentrations between 40 and 240 µg/ml. A pre-incubation with 1 µM α-
hederin also led to a reduced recruitment of β-arrestin 2 by 24.3 % (Figure 8).  
 
Figure 8: Recruitment of β-arrestin 2 to the β2AR. Cells were pre-incubated for 45 min with 
10 µM paroxetine or overnight with the indicated amounts of EA 575® and α-hederin, 
respectively, before stimulation with 0.5 µM terbutaline for additional 1h. Data represent the 
mean and S.D. of at least three independent experiments. (n≥14, ns: not significant, 
*p < 0.05) 
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4.6 EA 575® decreases IL-6 secretion from murine macrophages (J774.2) 
after LPS stimulation 
To initially check for a possible anti-inflammatory effect of EA 575® the murine macrophage 
cell line J774.2 was stimulated with 10 ng/ml LPS and the influence of extract pre-incubation 
on IL-6 secretion was measured by ELISA. As control, J774.2 cells were incubated with 5 µM 
corticosterone which inhibited the IL-6 secretion by 46.2 %. EA 575® was able to inhibit IL-6 
secretion dose-dependently in a concentration range from 40 to 160 µg/ml. The highest 
concentration of 160 µg/ml EA 575® inhibited IL-6 secretion significantly by 31.6 %, 80 µg/ml 
EA 575® by 25.4 % (Figure 9).  
 
 
Figure 9: Influence of EA 575® on the IL-6 secretion from J.774.2 cells induced by 10 ng/ml 
LPS. Corticosterone (5 µM) was used as control. Data represent the mean and S.D. of at 
least three independent experiments. (n≥8, ns: not significant, * p<0.05.) 
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4.7 Influence of EA 575® on NFκB transcriptional activity after TNFα 
stimulation 
As reported previously, luciferases under the control of NFκB response elements are suitable 
to verify influences on NFκB transcriptional activity [16]. Therefore HEK cells as well as THP-
1 cells were transfected with a Nanoluc-PEST based NFκB reporter system and NFκB 
transcriptional activity after LPS and TNFα stimulation was monitored. First HEK Nanoluc-
PEST cells were stimulated with 25 ng/ml TNFα and within this experiment a dose-depended 
decrease in NFκB activity after pre-incubation with 40, 80 or 240 µg/ml EA 575® by 31.0, 
34.3, and 42.0 %, respectively, was found (Figure 10).  
 
Figure 10: Transcriptional activity of NFκB in HEK Nanoluc-PEST cells after pre-treatment 
with the indicated amounts of EA 575® for 8h. After 5 h of pre-treatment, cells were 
stimulated for further 3 h with 25 ng/ml TNFα. Data represent the mean and S.D. of at least 
three independent experiments. (n≥30, * p<0.05) 
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Bacteria are recognized by the immune systems through the TLR receptors. In experimental 
approaches bacterial infections are mimicked with LPS which is recognized by TLR4. As 
HEK cells do not express TLR4, THP-1 cells were transfected with the Nanoluc-PEST 
construct and stimulated with 10 ng/ml LPS. Pre-incubation with EA 575® in concentrations 
between 40 and 240 µg/ml also showed a dose-dependent drop in NFκB activity by 5.8, 12.1, 
and 25.4 %, respectively, which were significant for concentrations of 80 and 240 µg/ml 
(Figure 11).  
 
Figure 11: NFκB activity in THP-1 Nanoluc-PEST cells after pre-treatment with different 
concentrations of EA 575® for 8h. After 5 h of pre-treatment, cells were stimulated for further 
3 h with 10 ng/ml LPS. Data represent the mean and S.D. of at least three independent 
experiments. (n≥24, ns: not significant, *p < 0.05) 
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4.8 Translocation of NFκB into the nucleus 
NFκB transcriptional activity requires the translocation of NFκB into the nucleus. To check 
whether the decreased transcriptional activity is due to an impaired NFκB translocation an 
immunofluorescent staining against NFκB subunit RelA in HEK 293 and J774.2 cells was 
performed. In both cell lines translocation of RelA after stimulation with TNFα or LPS is less 
pronounced when cells were pre-incubated with different concentrations of EA 575®. The 
effect was more obvious in J774.2 cells (Figure 12).  
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Figure 12: Translocation of NFκB subunit RelA into the nucleus visualized by immunostaining 
with a primary antibody against RelA and a secondary Cy3 coupled antibody. HEK cells A) 
unstimulated, C) stimulated with 25ng/ml TNFα for 50 min, E) pre-incubated for 8 h with 240 
µg/ml EA 575® and stimulated with 25 ng/ml TNFα for 50 min. J774.2 cells B) unstimulated, 
D) stimulated with 100 ng/ml LPS for 60 min, F) pre-incubated for 8 h with 80 µg/ml EA 575® 
and stimulated with 100 ng/ml LPS for 60 min. The nuclei are stained with Hoechst 33528. 
The scale bars correspond to 10 µM. Pictures are representative for three independent 
experiments. 
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4.9 Western blot against phosphorylated IκBα and RelA 
IκBα needs to be phosphorylated at Ser32 to dissociate from NFκB which allows NFκB to 
translocate into the nucleus [17]. The influence of EA 575® on this phosphorylation was 
investigated by a western blot analysis. HEK cells stimulated with 25 ng/ml TNFα for 10 min 
revealed an increased phosphorylation of IκBα. Pre-incubation with 240 µg/ml EA 575® 
significantly lowered the TNFα-induced IκBα phosphorylation by 26.4 % (Figure 13).  
 
Figure 13: Western blot analysis of phosphorylated IκBα (pIκBα) in HEK cells with or without 
pre-treatment with 240 µg/ml EA 575® and stimulation with 25 ng/ml TNFα for additional 10 
min. Data represent the mean and S.D. of at least three independent experiments. (n≥8, 
*p < 0.05) 
 
IKKβ is accountable for phosphorylation of IκBα at Ser32 as well as for the phosphorylation 
of RelA at Ser536 [18]. The influence of EA 575® on RelA phosphorylation was also 
investigated by a western blot analysis. HEK cells pre-treated with 240 µg/ml EA 575® and 
subsequently stimulated with 25 ng/ml TNFα revealed an increased formation of 
phosphorylated RelA (pRelA), which reached a statistically significant level 10 min (Figure 
14). 
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Figure 14: Western blot analysis of phosphorylated RelA (pRelA) in HEK cells with or without 
pre-treatment with 240 µg/ml EA 575® for 8 h and stimulation with 25 ng/ml TNFα for the 
indicated time. Data represent the mean and S.D. of at least three independent experiments. 
(n≥3, *p < 0.05) 
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4.10 Protein fragment complementation assay with RelA-cVenus and IκBα-
nVenus 
 
 
Figure 15: Principle of the protein fragment complementation measurements. Via a 
plasmid transfection two constructs were introduced into HEK cells. One composed of 
RelA with the C-terminus of Venus (RelA-cVenus) and the other one of IκBα with the N-
terminus of Venus (IκBα-nVenus). Prior to stimulation NFκB and IκBα are complexed 
and venus is composed of its two halves. Therefore, a fluorescence can be measured at 
550 nm (Excitation at 515 nm). After stimulation with TNFα the NFκB:IκBα complex 
dissociates which decreases the fluorescence intensity.   
 
 
 
Results 
 
36 
 
Phosphorylation of IκBα at Ser32 is known to influence the stability of NFκB:IκBα complexes. 
Therefore, the dissociation of the complex was determined via a protein fragment 
complementation of IκBα tagged with nVenus and NFκB subunit RelA tagged with cVenus 
(Figure 15). 
Stimulation of HEK cells stably expressing RelA-cVenus and IκBα-nVenus with 10 ng/ml 
TNFα led to the disintegration of the complex which can be measured by a drop in 
fluorescence intensity at 550 nm (Excitation at 515 nm). 
Pre-incubation with 160 µg/ml EA 575® for 8 h led to a significant increase of the RelA:IκBα-
Venus complex stability under TNFα stimulating conditions. After 3 h of TNFα stimulation 
13.9 % more fluorescence was preserved with EA 575® pre-treatment compared to TNFα 
stimulation alone. Lower concentrations of EA 575® didn´t significantly influence the 
IκBα:NFκB complex stability (Figure 16).  
 
Figure 16: Dissociation of the RelA:IκBα-Venus complex measured by a protein fragment 
complementation with or without pre-treatment for 8 h with the indicated amounts of EA 575® 
and after TNFα stimulation for additional 3 h. Data represent the mean and S.D. of at least 
three independent experiments. (n≥20, ns: not significant, *p < 0.05) 
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4.11 Influence of β2-adrenergic receptor stimulation on NFκB transcriptional 
activity 
As reported previously there is a pronounced influence of β2-adrenergic signaling on 
inflammatory processes [19-21].  
To find out whether the observed influence of EA 575® on the β2-adrenergic signaling also 
contributes to its anti-inflammatory effect, the NFκB activity was measured under co-
stimulation with 1 µM terbutaline. Stimulation with 1 µM terbutaline for 8 h led to a significant 
decrease of the TNFα-induced NFκB transcriptional activity by 24.6 % (Figure 17). Like 
shown before, pre-incubation with EA 575® for 8 h also lowered the TNFα-induced NFκB 
transcriptional activity in a dose-dependent manner (Figure 17). The simultaneous treatment 
with EA 575® and terbutaline for 8 h had a synergistic inhibiting effect on TNFα-induced 
NFκB transcriptional activity by 41.4, 47.0, and 58.5 % with 40, 80 and 240 µg/ml EA 575®, 
respectively (Figure 17).  
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Figure 17: NFκB transcriptional activity in HEK Nanoluc-PEST cells pre-incubated with the 
indicated amounts of EA 575® for 8 h, co-stimulated with 1 µM terbutaline for 8 h. After 5 h of 
pre-treatment, cells were stimulated for further 3 h with 25 ng/ml TNFα. Data represent the 
mean and S.D. of at least three independent experiments. (n≥12, *p < 0.05) 
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β-Arrestins are thought to be involved in the β2-adrenergic impact on inflammatory processes 
[22]. The influence of β-arrestins on the TNFα-induced NFκB transcriptional activity under 
terbutaline-stimulating conditions was investigated using HEK β-arrestin 1/2 KO Nanoluc-
PEST cells. In these cells the effect of EA 575® was less pronounced than in HEK Nanoluc-
PEST cells (Figure 18). Dose-dependent inhibition was first significant at a concentration of 
80 µg/ml EA 575®, compared to 40 µg/ml EA 575® in HEK cells expressing β-arrestins. 
Terbutaline was not able to inhibit the NFκB transcriptional activity in HEK β-arrestin 1/2 KO 
Nanoluc-PEST cells. Equally the synergistic inhibitory effect of EA 575® and terbutaline, 
observed in HEK Nanoluc-PEST cells, was abolished in HEK β-arrestin 1/2 KO Nanoluc-
PEST cells. 
 
 
Figure 18: NFκB transcriptional activity in HEK β-arrestin 1/2 KO Nanoluc-PEST cells pre-
incubated with the indicated amounts of EA 575® for 8 h, co-stimulated with 1 µM terbutaline 
for 8 h. After 5 h of pre-treatment, cells were stimulated for further 3 h with 25 ng/ml TNFα. 
Data represent the mean and S.D. of at least three independent experiments. (n≥12, ns: not 
significant, *p < 0.05) 
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4.12 Stabilization of NFκB:IκBα complex under β2-adrenergic stimulating 
conditions 
A requirement for the transcriptional activity of NFκB is the release of NFκB from the complex 
with IκBα [23]. Using the protein fragment complementation assay the influence of terbutaline 
on the RelA:IκBα-Venus complex stability was investigated.  
Pre-incubation with terbutaline in concentrations between 0.1 and 10 µM were able to dose-
dependently stabilize the RelA:IκBα-Venus complex under TNFα stimulating conditions. This 
effect was significant for 1 µM and 10 µM terbutaline, stabilizing the complex by 13.4 % and 
13.8 %, respectively (Figure 19).  
 
Figure 19: Dissociation of RelA:IκBα-Venus complex measured by the protein fragment 
complementation in HEK cells pre-treated for 2 h with the indicated amounts of terbutaline 
and stimulated for additional 3 h with 10 ng/ml TNFα. Data represent the mean and S.D. of at 
least three independent experiments. (n≥40, ns: not significant, *p < 0.05) 
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In order to find out whether the NFκB:IκBα complex stabilizing effect of terbutaline is 
dependent on β-arrestins, the effect was tested on HEK β-arrestin 1/2 KO cells. Again it was 
found that terbutaline stabilizes the RelA:IκBα-Venus complex in a dose- dependent manner 
by 15.3 % with 1 µM terbutaline and by 17.9 % with 10 µM terbutaline (Figure 20). Thus, the 
stabilization of the RelA:IκBα-Venus complex appears to be β-arrestin independent. 
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Figure 20: Dissociation of RelA:IκBα-Venus complex measured by protein fragment 
complementation in HEK β-arrestin 1/2 KO cells pre-treated for 2 h with the indicated 
amounts of terbutaline and stimulated for additional 3 h with 10 ng/ml TNFα. Data represent 
the mean and S.D. of at least three independent experiments. (n≥12, ns: not significant, 
*p < 0.05)
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5 Discussion 
The ivy leaves dry extract EA 575® is well established for the improvement of symptoms in 
chronic-inflammatory bronchial diseases and in acute inflammations of the respiratory tract 
associated with cough.  
To characterize the ivy leaves dry extract used in this work, the ingredients hederacoside B, 
C, D, α-hederin, rutin, kaempferol-3-O-rutinoside, 3,4-, 3,5-, and 4,5-dicaffeoylquinic
 acid were detected by HPLC fingerprint analysis. Additionally, the amount of α-hederin was 
determined to adjust the extract concentrations to the appropriate α-hederin concentrations 
of 0.5 µM, 1 µM and 3 µM which cover the dynamic range of the extract suitable for cell 
experiments. 
The bronchospasmolytic and secretolytic effect of EA 575® seem to derive from the inhibition 
of β2AR internalization [3]. This process is initialised by a receptor phosphorylation through 
GRK2 after stimulation [24]. For α-hederin, considered to be one of the pharmacologically 
active compounds of EA 575®, it could be shown that the inhibited β2AR internalization under 
stimulating conditions is mediated by an indirect inhibition of GRK2 [11]. This leads to a 
reduced phosphorylation of β2AR at Ser355/356 (Figure 2). Inhibition of the β2AR 
phosphorylation at Ser355/356 by the direct GRK2 inhibitor paroxetine (Figure 3) was also 
shown to inhibit the receptor internalization [25].  
Dynamic mass redistribution (DMR) is a label-free technique to examine signaling events in 
living cells. In this technique, the wavelength of reflected light changes depending on the 
optical density of the cells in the adjacent area above the sensor. The optical density of cells 
changes upon stimulation with appropriate signaling molecules, like terbutaline for β2AR [26]. 
Special focus of DMR rests on the signaling pathway of GPCRs, like the β2AR. Therefore, 
DMR was chosen to compare the influence of α-hederin and EA 575® on the β2AR signaling 
pathway, to that of the direct GRK2 inhibitor paroxetine. Terbutaline induced a dose-
dependent positive wavelength shift (Figure 4). Thus, stronger stimulation of β2AR led to a 
higher wavelength shift. Inhibition of GRK2, either with α-hederin or EA 575®, or with its direct 
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inhibitor paroxetine altered the terbutaline-induced wavelength shift (Figure 5) like 
heightened doses of terbutaline did. The terbutaline-induced wavelength shift was 
specifically mediated by the β2AR, as pre-treatment with the antagonist ICI 118,551 almost 
completely abolished the positive wavelength shift (Figure 5).   
DMR functionality was further controlled by stimulation with the muscarinic M2 agonist 
carbachol and the prostaglandin receptor agonist PGE1 (Figure S 10). Interestingly, an 
impact of α-hederin on carbachol and PGE1 induced wavelength shift was not observed. 
It has been demonstrated that GRK2 mediated phosphorylation of β2AR is followed by 
recruitment of β-arrestins to β2AR to continue with the internalization process. To elucidate 
whether or not the observed effect of α-hederin, EA 575®, and paroxetine depends on β-
arrestins, the measurements were repeated in β-arrestin knock out (KO) cells. As shown in 
Figure 6 the terbutaline induced wavelength shift could not be altered by pre-incubation with 
paroxetine, α-hederin, or EA 575®, respectively, in β-arrestin KO cells. It seems, however, as 
if the altered wavelength shift is associated with an inhibition of β-arrestin dependent 
receptor internalization. 
To further verify the impact of EA 575® on β-arrestin 2 dependent β2AR signaling, β-arrestin 2 
recruitment was measured in a PathHunter® assay. Within this assay α-hederin exhibited an 
inhibitory effect on β-arrestin 2 recruitment under stimulating conditions. Similarly effective as 
α-hederin, EA575® reduces β-arrestin 2 recruitment, indicating that there are no synergistic 
or opposite effects arriving from other extract ingredients (Figure 8).  
Glycyrrhizin, structural related to α-hederin, shows widely similar influences on the β2AR 
pathway, like inhibition of both GRK2 mediated phosphorylation and receptor internalization 
[27]. The authors of [27] speculated about a membrane associated effect mostly because of 
the amphiphilic structure which shares glycyrrhizin with α-hederin. Remarkably, in giant 
unilamellar vesicles α-hederin forms complexes with cholesterol [28]. Membrane changes 
like cholesterol depletion were demonstrated to greatly impact clathrin-mediated endocytosis 
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[29, 30]. The β2AR is also internalized via clathrin-coated pits and it was additionally shown 
that downstream signaling of the receptor is highly influenced by changes in the membrane 
integrity [31, 32]. It is interesting to note that cholesterol depletion does not necessarily lead 
to an attenuated receptor internalization, as shown for the PTGER1 (PGE receptor) [32].  
Besides its bronchospasmolytic and secretolytic properties there is one publication 
describing an anti-inflammatory effect on chronic bronchitis after EA 575® inhalation but the 
mode of action remains unclear and needs to be further investigated [33]  
Since IL-6 is thought to play important roles in several inflammatory diseases which also 
refer to asthma and chronic bronchitis [34, 35], it was first checked for an inhibitory effect of 
EA 575® on IL-6 release from murine macrophages (J774.2).  
As shown in the literature [36], J774.2 cells pre-treated with different concentrations of EA 
575® and subsequently stimulated with LPS revealed a dose-dependent decrease in IL-6 
release, statistically significant at 80 µg/ml. Pre-treatment with corticosterone served as 
control demonstrating an expected decrease in IL-6 release (Figure 9).  
Expression and release of interleukins are mostly regulated through the NFκB pathway, so 
the influence of EA 575® on this pathway was measured first by immunostaining of NFκB 
subunit RelA. LPS induced translocation of NFκB in J774.2 cells was reduced by pre-
treatment with 240 µg/ml EA575® (Figure 12). Similar results were obtained in HEK cells 
stimulated with TNFα (Figure 12). TNFα and LPS do not bind to the same receptor but their 
different signaling pathways both lead to NFκB translocation into the nucleus. Thus, EA 575® 
does not impact a single receptor pathway in inflammation, but rather manipulates processes 
to activate NFκB, like IKKβ mediated phosphorylation or NFκB:IκBα complex stability. NFκB 
transcriptional activity was measured as nanoluciferase activity in HEK cells stably 
transfected with a nanoluciferase coupled to an NFκB binding sequence. EA 575® dose-
dependently inhibited TNFα-induced NFκB activity in these HEK Nanoluc-PEST cells at 
concentrations between 40 and 240 µg/ml (Figure 10). Similar to stimulation of TNFR1 in 
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HEK Nanoluc-PEST cells, stimulation of TLR4 with LPS in THP-1 Nanoluc-PEST cells led to 
an increased luciferase activity showing transcriptional activity of NFκB. This was dose-
dependently inhibited by pre-incubation with EA 575® in concentrations between 80 and 240 
µg/ml (Figure 11). TLR4 is a membrane associated receptor e.g. responsible for recognition 
of cell wall compounds of bacteria and signals through NFκB, even if the associated 
downstream kinases partially differ to that of TNFR1 pathway.  
Schröfelbauer et al. demonstrated that glycyrrhizin, structural related to α-hedrin, also inhibits 
NFκB dependent cytokine secretion like TNFα and IFNγ from murine macrophages after 
TLR4 stimulation with LPS [37]. For the mode of action, they speculated that this finding 
results from an impact on membrane structures like lipid rafts, which are also important for 
TLR signaling [38]  
For translocation and transcriptional activity of NFκB dissociation from its inhibitor IκBα is 
required. Therefore, IκBα is phosphorylated by IKKβ, which is arranged in a kinase complex 
with IKKα and their regulating unit NEMO (also called IKKγ). The phosphorylation site of IκBα 
is located at Ser32, which dictates its ubiquitination and subsequent degradation via the 
proteasome [17, 39].  
In HEK cells stimulated for 10 min with TNFα, phosphorylation of IκBα at Ser32 was 
significantly lowered after pre-incubation with EA 575® (Figure 13), probably leading to an 
enhanced complex stability of NFκB:IκBα. 
IKKβ also phosphorylates NFκB subunit RelA at Ser536. After pre-incubation with EA 575®, 
phosphorylation was continuously enhanced to a statistically significant level 10 min after 
TNFα stimulation (Figure 14).  
While the phosphorylation of IκBα is commonly known to induce its dissociation from RelA, 
phosphorylation of RelA and the subsequent processes are more complex. Several 
phosphorylation sites are known and many of them positively regulate NFκB transcripitional 
activity [40] As one example for negative regulation, phosphorylation at Ser536 was shown to 
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reduce NFκB translocation into the nucleus and to reduce transcriptional activity [41]. While it 
is not completely clarified how the IKK complex is activated upon stimulation, it was shown 
that NEMO acts as a scaffold protein directing the kinase to its phosphorylation sites, e.g. to 
IκBα or RelA, thereby influencing the affinity of IKKβ to different target proteins [42]. This 
affinity can be changed, e.g., by target inaccessibility, which Schröfelbauer et al. 
demonstrated with a RelA mutant that could no longer be phosphorylated. They 
hypothesized that this also might be a regulation point which supports the inhibiting effect of 
a lower IκBα phosphorylation rate. 
To investigate the effect of dropped phosphorylation of IκBα, the stability of NFκB:IκBα 
complex was measured in a protein fragment complementation (PFC) assay. Therefore, a 
HEK cell line was generated, overexpressing both RelA coupled to C-terminal part of Venus 
and IκBα coupled to N-terminal part of Venus as firstly described by Yu et al [8]. In 
unstimulated HEK cells IκBα remains in complex with RelA resulting in the formation of the 
fluorescence protein. Stimulation with TNFα induces dissociation of the complex and thereby 
also to decomposition of Venus, which can be measured as a fluorescence decrease (Figure 
15). Compared to TNFα stimulation alone pre-incubation with EA 575® reduced the TNFα-
induced decrease in fluorescence intensity, demonstrating a higher amount of assembled 
fluorescent Venus fragments and thus of the RelA:IκBα complex (Figure 16). Taken together, 
the findings presented in this work clearly indicate an impact of EA 575® on inflammatory 
processes through an inhibitory impact on the NFκB pathway. 
As discussed above previous work dealing with EA 575® effects mostly focussed on the 
β2AR pathway for its importance in bronchospasmolysis and secretolysis. This work focussed 
on the NFκB pathway for its crucial relevance in inflammation. These two pathways have 
been demonstrated in the literature to display crosstalk via the scaffold protein β-arrestin. It is 
thought to interact with IκBα, thereby probably stabilizing the complex with NFκB which 
results in an anti-inflammatory effect [22, 43, 44]. Since β-arrestin 2 recruitment was already 
shown to be influenced by EA 575® (see above) it seemed likely that EA 575® also affects 
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the crosstalk between the NFκB and β2AR pathways. The influence of β2AR stimulation on 
NFκB activity was primarily measured in the HEK Nanoluc-PEST cells. Cells were stimulated 
with terbutaline prior to TNFα stimulation, and NFκB transcriptional activity was measured 
through nanoluciferase activity. Terbutaline co-stimulation significantly inhibited NFκB 
transcriptional activity, which demonstrates the crosstalk between these pathways. Additional 
pre-incubation with EA 575® exhibited a synergistic inhibiting effect with terbutaline 
stimulation on TNFα induced NFκB transcriptional activity (Figure 17). To check whether this 
effect depends on β-arrestins the same experiments were performed in HEK β-arrestin 1/2 
KO Nanoluc-PEST cells. Knock-out of β-arrestin 1/2 abolished the terbutaline induced drop 
in NFκB transcriptional activity after TNFα stimulation. This clearly shows that the inhibitory 
effect of terbutaline on NFκB transcriptional activity, and also the synergistic EA 575® effect, 
depends on β-arrestin. This finding is supported by glycyrrhizin, structural related to α-
hederin, that was also shown to exhibit a synergistic effect with a β2-agonist on NFκB 
transcriptional activity [45]. 
The synergistic effect of EA 575® and terbutaline, observed in HEK Nanoluc-PEST cells was 
absent as expected, in HEK β-arrestin 1/2 KO Nanoluc-PEST cells. In contrast the inhibiting 
effect of EA 575® pre-incubation on the NFκB transcriptional activity was found even in HEK 
β-arrestin 1/2 KO cells. Although it was not as pronounced as in HEK Nanoluc-PEST cells, it 
points on an additional, β-arrestin independent, influence of EA 575® on the NFκB pathway 
(Figure 18). This could also derive from extract ingredients that were shown previously to 
influence NFκB driven inflammatory processes. For example, rutin as well as 3,5- and 4,5-
dicaffeoylquinic acid inhibit the NFκB dependent iNOS gene transcription and as a result the 
synthesis of nitric oxide whereas chlorogenic acid reduces LPS induced NFκB dependent 
cyclooxygenase-2 (COX-2) expression in RAW 264.7 cells [46-48]. Furthermore, 3,4-
dicaffeoylquinic acid inhibits the phorbol-12-myristate-13-acetate induced COX-2 expression 
in RAW264.7 cells by blocking the catalytic activity of JNK/p38 MAP kinases and the 
activation of C/EBPβ and AP-1 [49]  
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As it was suggested by Witherow et al. and Gao et al. that the binding of β-arrestin to IκBα 
stabilizes the NFκB:IκBα complex [43, 44], this issue was investigated by PFC. The PFC 
assay confirmed that terbutaline stimulation enhanced complex stability of NFκB:IκBα under 
TNFα stimulating condition (Figure 19), but that β-arrestin knock-out did not change this 
effect (Figure 20). Thus, the assumed stabilizing effect of β-arrestin could not be confirmed 
[43, 44]. The data presented in this work show that the stabilizing effect of a β2AR stimulation 
on the NFκB:IκBα complex is not β-arrestin dependent. Therefore, the inhibiting effect of 
β2AR signaling on transcriptional NFκB activity seems to arrive from a downstream event of 
the NFκB pathway. Another possible explanation could be a dual impact of β2AR signaling on 
the NFκB pathway. Thus, the stabilized complex would not depend on β-arrestins, while a 
further downstream event depends on β-arrestins and influences NFκB transcriptional 
activity. In consideration of the multiple binding partners of β-arrestin it seems likely that 
other proteins involved in the NFκB pathway are influenced by β-arrestin [50]. Therefore, the 
mechanisms by which β2-agonists and EA575® impact the stability of NFκB:IκBα complex 
has to be further investigated. 
In conclusion, the data presented in this work give information about the mode of action of 
EA575® induced inhibition of β2AR internalization. Additionally the results clearly confirm an 
anti-inflammatory effect of EA 575® mediated through inhibition of the NFκB transcriptional 
activity. It is particularly notable that this effect could be heightened by co-stimulation with 
terbutaline, which is of relevance for chronic inflammatory diseases of the respiratory tract 
like asthma and COPD which are commonly treated with β2-agonists. 
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7  Appendix 
7.1 Supplemental material 
Table S 1: Retention times of identified substances in EA 575® CID-100048 
Substance Retention time in EA 
575® chromatogram 
[min] 
Retention time of reference substance 
[min] 
Rutin 24.85  
 
24.04 
3,4 DCA 27.38 26.16 
Kaempferol-3-O-
rutinoside 
27.93 28.04 
3,5 DCA 28.45 27.28 
4,5 DCA 29.94 29.10 
Hederacoside C 34.31 34.04 
Hederacoside D 34.68 34.45 
Hederacoside B 36.83 36.56 
α-Hederin 43.08 41.79 
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Table S 2: HPLC determination of α-hederin reference substance 
 Reference measurement 1 Reference measurement 2  
Sum of area of 
integrated peaks 
8722.38 
 
8664.47 
 
Area under peak of α-
hederin 
7157.09 
 
7160.92 
 
Calculated purity [%] 82.05 82.65 
Injected amount [µg] 25.8 25.8 
Area equal to 1 µg  338.04 335.82 
 
 
Table S 3: Calculation of α-hederin amount in EA 575® CID-100048 
 Extract analysis 1 Extract analysis 2 
α-Hederin peak area 105.92 107.34 
Calculated amount [%]  0.785 0.796 
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Figure S 1: Representative HPLC chromatogram of α-hederin reference substance. 
Chromatogram was obtained by the method described in chapter 3.1 
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Figure S 2: Nanoluc-PEST plasmid card, pNF-KB-D2EGFP vector was used as template 
(Clontech, Mounten View, California, USA), Nanoluc-PEST sequence was cut from 
pNL1.2[NlucP] (Promega, Madison, Wisconsin, USA). 
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Figure S 3: Agarose gel analysis of enzymatic digestions A) 1 kb DNA ladder (Thermo Fisher 
Scientific), B) Nanoluc-PEST digested by BglI expected band sizes 4597+1299 bp C) 
Nanoluc-PEST digested by PstI expected band sizes 3155+2741 bp. Both restriction 
enzymes were obtained from Thermo Fisher Scientific 
 
 
Figure S 4: pCDNA3.1/Zeo_IkBa-nVenus plasmid card, plasmid was constructed by GeneArt 
(Regensburg, Germany). 
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Figure S 5: pCDNA3.1/Hygro_cVenus-RelA plasmid card, plasmid was constructed by 
GeneArt (Regensburg, Germany). 
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Figure S 6: Agarose gel analysis of enzymatic digestions A) Quick-Load® Purple 2-Log DNA 
Ladder (0.1 - 10.0 kb) (NEB, Ipswich, Massachusetts, USA), B) pCDNA3.1/Zeo_IkBa-
nVenus digested by BglI expected band sizes 3374, 1723, 1143, 122, 71 bp C) 
pCDNA3.1/Zeo_IkBa-nVenus digested by PstI; expected band sizes 5395, 354, 351, 183, 
150 bp. Both restriction enzymes were obtained from Thermo Fisher Scientific. 
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Figure S 7: Agarose gel analysis of enzymatic digestion A) pCDNA3.1/Hygro_c-Venus-RelA 
digested by EcoRI, expected band sizes 4375, 2182, 933 bp, B) 1 kb DNA ladder (Thermo 
Fisher Scientific) Restriction enzyme was obtained from Thermo Fisher Scientific. 
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Figure S 8: Quick start protocol for CompactPrep Midi Prep (Qiagen®). For more detailed 
protocol visit https://www.qiagen.com/us/shop/sample-technologies/dna/plasmid-
dna/compactprep-plasmid-midi-kits/#orderinginformation 
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Figure S 9: Influence of overnight pre-incubation with 1 µM α-hederin on carbachol induced 
dynamic mass redistribution measurement in HEK β2AR GFP cells. Carbachol stimulation 
was performed with 100 µM after baseline acquisition for 300 s. 
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Figure S 10: Influence of overnight pre-incubation with 1 µM α-hederin on PGE1 induced 
dynamic mass redistribution measurement in HEK β2AR GFP cells. PGE1 stimulation was 
performed with 10 µM after baseline acquisition for 300 sec. 
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Figure S 11: Assay relevant abstracts of PathHunter® eXpress β-Arrestin Human and 
Ortholog GPCR Assays. For whole manual visit: https://www.discoverx.com/tools-
resources/document-resource-library/documents/updated-cell-culture-protocol-technical-
bulletin 
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Figure S 12: Assay relevant abstracts of Novex Mouse IL-6 ELISA kit. For whole manual 
visit: http://www.thermofisher.com/order/catalog/product/KMC0061 
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Figure S 13: Assay relevant abstracts of NanoGlo Luciferase assay system. For whole 
manual visit: https://www.promega.com/-/media/files/resources/protocols/technical-
manuals/101/nanoglo-luciferase-assay-system-protocol.pdf 
Supplemental material 
 
65 
 
 
 
 
Figure S 14: Time- and dose-dependent NFκB transcriptional activity in TNFα stimulated 
HEK Nano-PEST cells.  
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Figure S 15: Time- and dose-dependent NFκB transcriptional activity in LPS stimulated THP-
1 Nano-PEST cells. 
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Figure S 16: Western blot of Ser536 phosphorylated RelA stimulated for the indicated time 
with 25 ng/ml TNFα.      
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Figure S 17: Western blot of Ser536 phosphorylated RelA stimulated for the indicated time 
with 25 ng/ml TNFα and pre-incubated for 8 h with 240 µg/ml EA 575® 
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Figure S 18: Western blot of Ser32 phosphorylated IκBα stimulated for the indicated time 
with 25 ng/ml TNFα and with or without pre-incuabtion with 240 µg/ml EA 575® for 8 h. 
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Figure S 19: Assay relevant abstracts of REVERT Total protein stain kit. For whole manual 
visit: https://www.licor.com/bio/pack_inserts/get_pack?filename=926-
11010_REVERTTotalProteinStainKit_988-15930_1459353647.pdf 
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